Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma - Top-Institutions - MDSpire

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

  • By

  • Frida Bugge Askeland

  • Vilhelm Hauge Bugge

  • Anne-Marie Rasmussen

  • Anna Lysén

  • Einar Haukås

  • Magnus Moksnes

  • Anette L. Eilertsen

  • Galina Tsykunova

  • Birgitte Dahl Eiken

  • Nils Morten Leknes

  • Jürgen Rolke

  • Vidar Stavseth

  • Eivind Samstad

  • Randi Fykse Hallstensen

  • Damian Szatkowski

  • Ariane Aasbø Hansen

  • Anita Smith Nilsen

  • Tobias S. Slørdahl

  • Pegah Abdollahi

  • Fredrik Schjesvold

  • December 22, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Nephrology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Nephrology

  • #4

    University of Arkansas for Medical Sciences (UAMS)
    University of Arkansas for Medical Sciences (UAMS)

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Nephrology

Original Source(s)

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

  • by Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen, Anna Lysén, Einar Haukås, Magnus Moksnes, Anette L. Eilertsen, Galina Tsykunova, Birgitte Dahl Eiken, Nils Morten Leknes, Jürgen Rolke, Vidar Stavseth, Eivind Samstad, Randi Fykse Hallstensen, Damian Szatkowski, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Pegah Abdollahi, Fredrik Schjesvold

  • December 22, 2025

Related Content

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma

The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.

  • by

  • March 24, 2026

  • 5 min